دورية أكاديمية
أعرض في EDS

Haplotype Structures and Protein Levels of TGFB1 in HPV Infection and Cervical Lesion: A Case-Control Study.

التفاصيل البيبلوغرافية
العنوان: Haplotype Structures and Protein Levels of TGFB1 in HPV Infection and Cervical Lesion: A Case-Control Study.
المؤلفون: Trugilo KP; Laboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Londrina 86057-970, PR, Brazil., Cebinelli GCM; Laboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Londrina 86057-970, PR, Brazil., Pereira ÉR; Laboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Londrina 86057-970, PR, Brazil.; Laboratory of Mutagenesis and Oncogenetics, Department of Biological Sciences, State University of Londrina, Londrina 86057-970, PR, Brazil., Okuyama NCM; Laboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Londrina 86057-970, PR, Brazil.; Laboratory of Mutagenesis and Oncogenetics, Department of Biological Sciences, State University of Londrina, Londrina 86057-970, PR, Brazil., Cezar-Dos-Santos F; Laboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Londrina 86057-970, PR, Brazil., Castilha EP; Laboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Londrina 86057-970, PR, Brazil., Flauzino T; Laboratory of Research in Applied Immunology, State University of Londrina, Londrina 86057-970, PR, Brazil., Hoch VB; Laboratory of Human Molecular Genetics, Department of Genetics, Federal University of Paraná, Curitiba 80060-000, PR, Brazil., Watanabe MAE; Laboratory of Studies and Applications of DNA Polymorphisms and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Londrina 86057-970, PR, Brazil., Guembarovski RL; Laboratory of Mutagenesis and Oncogenetics, Department of Biological Sciences, State University of Londrina, Londrina 86057-970, PR, Brazil., de Oliveira KB; Laboratory of Molecular Genetics and Immunology, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Londrina 86057-970, PR, Brazil.
المصدر: Cells [Cells] 2022 Dec 25; Vol. 12 (1). Date of Electronic Publication: 2022 Dec 25.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مواضيع طبية MeSH: Papillomavirus Infections*/genetics, Humans ; Female ; Haplotypes/genetics ; Genetic Predisposition to Disease ; Case-Control Studies ; Polymorphism, Single Nucleotide ; Transforming Growth Factor beta1/genetics
مستخلص: This study aimed to verify the role of TGFB1 variants (c.-1638G>A, c.-1347C>T, c.29C>T, and c.74G>C) in HPV infection susceptibility and cervical lesions development, and their impact on TGFB1 cervical and plasma levels. TGFB1 genotypes were assessed with PCR-RFLP and haplotypes were inferred for 190 HPV-uninfected and 161 HPV-infected women. TGFB1 levels were determined with immunofluorimetric assay. Case-control analyses were performed with logistic regression adjusted for possible confounders. Women carrying -1347TT or -1347CT+TT as well as those with 29CT, 29CC, or 29CT+CC were more likely to have HPV than -1347CC and 29TT carriers, respectively. Regarding haplotypes, the most frequent were *4 (GCTG) and *3 (GTCG). Women *4/*4 were less likely to have HPV than those with no *4 copy. Comparing the inheritance of *3 and *4, carriers of *3/*4 or *3/*3 were more susceptible to HPV than *4/*4. The TGFB1 plasma and cervical levels were higher in the infected patients. Plasma levels were also higher in infected women with low-grade lesions. HPV-infected patients carrying *3/Other and *3/Other+*3/*3 presented lower TGFB1 plasma levels than those with no copy of *3. TGFB1 variants could contribute to the comprehension of the TGFB1 role in HPV-caused cervical disease.
References: Am J Hum Genet. 2005 Mar;76(3):449-62. (PMID: 15700229)
Med Microbiol Immunol. 2019 Feb;208(1):49-58. (PMID: 30167873)
Lancet Infect Dis. 2007 Jul;7(7):453-9. (PMID: 17597569)
Arch Gynecol Obstet. 2012 Oct;286(4):1015-22. (PMID: 22699514)
Virology. 2013 Dec;447(1-2):63-73. (PMID: 24210100)
JAMA. 1991 Jan 23-30;265(4):472-7. (PMID: 1845912)
Hum Genet. 2006 Nov;120(4):461-9. (PMID: 16896927)
Braz J Infect Dis. 2016 Jan-Feb;20(1):61-8. (PMID: 26706020)
Int J Cancer. 2004 Oct 20;112(1):94-9. (PMID: 15305380)
J Biomed Sci. 2018 Sep 18;25(1):69. (PMID: 30227860)
Cancer Med. 2018 Oct;7(10):5217-5236. (PMID: 30589505)
Pathogens. 2022 Nov 19;11(11):. (PMID: 36422631)
Br J Plast Surg. 2004 Apr;57(3):215-21. (PMID: 15006522)
J Cancer Res Clin Oncol. 2018 Apr;144(4):645-655. (PMID: 29362917)
Nature. 2020 May;581(7809):434-443. (PMID: 32461654)
J Med Virol. 2019 Feb;91(2):317-325. (PMID: 30192406)
Am J Hum Genet. 2001 Apr;68(4):978-89. (PMID: 11254454)
Semin Cancer Biol. 2014 Jun;26:13-21. (PMID: 24316445)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Eur Cytokine Netw. 2016 Nov 1;27(4):81-89. (PMID: 28396298)
Virology. 2010 May 25;401(1):70-9. (PMID: 20206957)
Viral Immunol. 2006 Summer;19(3):468-80. (PMID: 16987065)
J Transl Med. 2012 Sep 03;10:183. (PMID: 22943793)
Transplantation. 1998 Oct 27;66(8):1014-20. (PMID: 9808485)
Methods Mol Biol. 2009;578:3-22. (PMID: 19768584)
Oncol Res. 2009;18(1):41-5. (PMID: 19911703)
Mem Inst Oswaldo Cruz. 2016 Nov;111(11):663-669. (PMID: 27783717)
Biomed Res Int. 2013;2013:146079. (PMID: 23936772)
Circulation. 2000 Jun 20;101(24):2783-7. (PMID: 10859282)
J Virol. 1990 Oct;64(10):4767-75. (PMID: 2168964)
World J Clin Oncol. 2014 Oct 10;5(4):753-63. (PMID: 25302175)
Int J Mol Sci. 2013 Jul 24;14(8):15376-85. (PMID: 23887657)
J Immunol Methods. 2000 Feb 3;234(1-2):117-22. (PMID: 10669776)
Bioinformatics. 2005 Jan 15;21(2):263-5. (PMID: 15297300)
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):177-82. (PMID: 12509516)
J Oncol. 2019 Oct 10;2019:3257939. (PMID: 31687023)
Infect Genet Evol. 2017 Sep;53:128-134. (PMID: 28552689)
Nucleic Acids Res. 1987 Apr 10;15(7):3188-9. (PMID: 3470709)
Gynecol Oncol. 2015 Oct;139(1):90-6. (PMID: 26241630)
J Cancer Res Clin Oncol. 2019 Aug;145(8):2013-2025. (PMID: 31177386)
J Clin Invest. 2017 Apr 3;127(4):1321-1337. (PMID: 28287407)
Eur J Obstet Gynecol Reprod Biol. 2008 Oct;140(2):241-4. (PMID: 18502564)
Dis Markers. 2007;23(4):213-27. (PMID: 17627057)
J Oncol. 2015;2015:587193. (PMID: 25883652)
Mol Biol Evol. 2016 Jul;33(7):1870-4. (PMID: 27004904)
Nat Rev Cancer. 2013 Nov;13(11):788-99. (PMID: 24132110)
Hum Mol Genet. 1999 Jan;8(1):93-7. (PMID: 9887336)
Am J Hum Biol. 2010 Mar-Apr;22(2):187-92. (PMID: 19639555)
Clin Cancer Res. 2010 Mar 1;16(5):1416-22. (PMID: 20179236)
فهرسة مساهمة: Keywords: polymorphism; rs1800468; rs1800469; rs1800470; rs1800471
المشرفين على المادة: 0 (TGFB1 protein, human)
0 (Transforming Growth Factor beta1)
تواريخ الأحداث: Date Created: 20230108 Date Completed: 20230110 Latest Revision: 20230206
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9818366
DOI: 10.3390/cells12010084
PMID: 36611878
قاعدة البيانات: MEDLINE
الوصف
تدمد:2073-4409
DOI:10.3390/cells12010084